Human immunodeficiency virus type 1 RNA (HIV-1 RNA) (HIV-1 RNA)

Human immunodeficiency virus type 1 (HIV-1) RNA is the fundamental genetic component of the virus, existing as a dimer of single-stranded, positive-sense genomic RNA (gRNA) within the virion and as a variety of spliced and unspliced transcripts within the host cell. Beyond its primary role in encoding the viral proteome, the RNA contains highly conserved structural motifs that are essential for the viral life cycle, including the Trans-activation Response (TAR) element for transcription elongation and the Rev Response Element (RRE) for nuclear export. These structures serve as critical interaction hubs for both viral and host proteins, making them attractive targets for novel therapeutic strategies [1, 3, 7]. As a therapeutic target, HIV-1 RNA is primarily addressed through nucleic acid-based technologies, such as RNA interference (RNAi) and antisense oligonucleotides, which aim to silence viral gene expression or induce the degradation of the viral genome itself [6, 10]. Modern research is also exploring small molecules and branched peptides designed to bind specific RNA secondary structures, offering a potential pathway to bypass the drug resistance commonly seen with protein-targeted antiretroviral therapies [18, 22]. However, the extreme genetic diversity and high mutation rate of HIV-1 present significant challenges for sequence-specific targeting, necessitating the use of combinatorial RNAi approaches to prevent viral escape [15, 17]. Furthermore, achieving efficient intracellular delivery and avoiding the triggering of innate immune responses remain primary hurdles in the clinical development of RNA-targeted HIV therapies [2, 8].

Other names

HIV viral RNAHIV-1 genomic RNAHIV transcriptHIV-1 mRNAViral RNA genomevRNA

Drugs targeting HIV-1 RNA function through several mechanisms: 1) RNA interference (RNAi)-mediated degradation of viral transcripts using siRNAs or shRNAs; 2) Antisense inhibition to block the translation of viral genes or alter suboptimal splicing; 3) Disruption of essential protein-RNA interactions, most notably the binding of Tat to the Trans-activation Response (TAR) element and Rev to the Rev Response Element (RRE); 4) Inhibition of the nuclear export of unspliced or partially spliced viral RNAs; and 5) Modulation of programmed ribosomal frameshifting or RNA chemical modifications (e.g., m6A) that are critical for viral fitness and protein ratios.